Recursion Pharmaceuticals Inc. (RXRX): Price and Financial Metrics Recent IPO
GET POWR RATINGS... FREE!
RXRX Stock Price Chart Interactive Chart >
RXRX Price/Volume Stats
| Current price | $26.81 | 52-week high | $42.81 |
| Prev. close | $24.26 | 52-week low | $17.80 |
| Day low | $24.13 | Volume | 3,063,600 |
| Day high | $27.38 | Avg. volume | 479,092 |
| 50-day MA | $28.17 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 4.52B |
Recursion Pharmaceuticals Inc. (RXRX) Company Bio
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people’s lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.
Latest RXRX News From Around the Web
Below are the latest news stories about Recursion Pharmaceuticals Inc that investors may wish to consider to help them evaluate RXRX as an investment opportunity.
Recursion Reports Second Quarter 2021 Financials and Provides Business UpdatesRecursion (Nasdaq: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, today reported financial results and business updates for its second quarter ending June 30, 2021. |
What You Need To Know About Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Investor CompositionThe big shareholder groups in Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX ) have power over the company. Generally... |
Recursion Announces Therapeutics Advisory Board, Chaired by Joseph Miletich, MD, PhDRecursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering, today announced its formation of a Therapeutics Advisory Board (TAB), chaired by Joseph Miletich, MD, PhD. The TAB will guide Recursion's executive team and Board of Directors on the key challenge of developing medicines at scale from its tech-enabled drug discovery pipeline and bringing them to the pat |
Recursion Opens Child Care Center to Support EmployeesRecursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering, today announced the opening of its child care center, adjacent to Recursion's Salt Lake City headquarters. |
Recursion Signs Lease With Vestar for an Additional 100,000 sf of Space at the Gateway in Downtown Salt Lake CityRecursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering, today announced that it is doubling the size of its headquarters at The Gateway in downtown Salt Lake City, signing a new lease with Vestar for an additional 100,000 square feet. The Gateway is a mixed-use lifestyle and entertainment district, featuring 1.2 million square feet of retail, dining and offi |
RXRX Price Returns
| 1-mo | 35.06% |
| 3-mo | -28.35% |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...